Table 3. Proportion of adult and child participants with baseline antibody titers ≤ 80 who seroconverted between baseline and 14 days after the first dose of vaccine, and 14 days after the second dose of vaccine (among participants with paired blood specimens).
| No. of participants with baseline antibody titers ≤ 80 | No. of participants with baseline antibody titers ≤ 80 who seroconverteda between baseline & 14 days after dose 1 (%) | No. of participants with baseline antibody titers ≤ 80 who seroconvertedb between baseline & 14 days after dose 2 (%) | |
|---|---|---|---|
| Adults | |||
| V. cholerae O1 Inaba | 33 | 30 (91) | 30 (91) |
| V. cholerae O1 Ogawa | 15 | 14 (93) | 14 (93) |
| V. cholerae O139 | 94 | 19 (20) | 20 (20) |
| Children | |||
| V. cholerae O1 Inaba | 48 | 46 (96) | 46 (96) |
| V. cholerae O1 Ogawa | 36 | 33 (92) | 36 (100) |
| V. cholerae O139 | 96 | 25 (26) | 18 (18.8) |
aNumber of participants with ≥ 4 fold rise in titers of serum vibriocidal antibodies between baseline and 14 days after dose 1
bNumber of participants with ≥ 4 fold rise in titers of serum vibriocidal antibodies between baseline and 14 days after dose 2